P-A-C

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of P-A-C

What is P-A-C and Its Pharmacological Classification?

P-A-C is a fixed-dose combination medicine containing the active ingredients Acetylsalicylic Acid and Caffeine. This orally administered medication is classified as an analgesic combination. It blends two distinct pharmacological components: Acetylsalicylic Acid functions as a Nonsteroidal Anti-inflammatory Drug (NSAID), while Caffeine acts as a Central Nervous System (CNS) stimulant. The combination of these two agents is used for general pain management, utilizing multiple biological pathways to provide relief.

The Composition of P-A-C: A Dual-Action Analgesic

The core composition pairs Acetylsalicylic Acid (ASA) with Caffeine, where Caffeine functions as a pharmacodynamic adjuvant. In this role, Caffeine is included to enhance the efficacy of the ASA rather than acting as a primary pain reliever on its own. This formulation is characterized by a dual-action analgesic mechanism, distinguishing it from single-ingredient NSAID products. The combination is delivered through common oral dosage forms, typically tablets or caplets, which ensure the fixed ratio of ingredients is consistently administered.

General Therapeutic Purpose of the P-A-C Combination

The principal therapeutic purpose of P-A-C is to provide relief from mild to moderate pain and general discomfort, such as muscle aches. The medicine leverages the complementary actions of the NSAID and the stimulant to produce a synergistic response. This combination is designed to offer an enhanced response for managing various types of acute pain, serving as a comprehensive option for general pain management.

Regulatory References

  1. pharmacodynamic adjuvant
  2. NCBI Bookshelf: StatPearls

What side effects are possible with P-A-C?

Official Safety Profile and Adverse Reactions

The safety profile of P-A-C, a combination of Acetylsalicylic Acid (ASA) and Caffeine, is defined by the known effects of its two active components, as documented in regulatory sources.

Adverse reactions are officially classified based on their frequency and impact on various System-Organ Classes.


Frequency and System Classification

Adverse reactions that are frequently documented often involve the Gastrointestinal System and the Nervous System.

  • Common Reactions may include gastrointestinal disturbances such as dyspepsia, nausea, and abdominal discomfort, primarily linked to the ASA component. Nervous system effects often include insomnia, nervousness, and dizziness, primarily due to the stimulating effects of Caffeine.
  • Rare Reactions include more serious events such as tinnitus (ringing in the ears), signs of abnormal liver function, and hypersensitivity reactions (e.g., skin rash or bronchospasm).

Serious Adverse Reactions and Restrictions

Regulatory documents highlight specific serious adverse reactions that are clinically significant. These include overt and serious Gastrointestinal Hemorrhage and ulceration, which are associated with the ASA component, particularly at higher doses or with long-term use.

  • The risk of Reye's Syndrome, a rare but severe condition, is a primary regulatory constraint. The combination is contraindicated for use in children and teenagers recovering from viral illnesses (e.g., chickenpox or flu) due to this documented association.
  • Official safety constraints also include avoiding use in individuals with active peptic ulcer disease, severe hepatic or renal impairment, and a known history of hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).

These classifications establish the regulatory boundaries for the medicine’s risk profile, focusing purely on documented safety characteristics.

Overdose and Emergency Response

P-A-C is a combination product containing acetaminophen, aspirin, and caffeine. An overdose can be fatal due to the toxicity of its individual components, particularly acetaminophen and aspirin. Exceeding the recommended dosage, whether intentionally or accidentally, requires immediate medical attention.

Overdose symptoms can be complex and may include initial signs of nausea, vomiting, stomach pain, and sweating. Later symptoms are often related to the accumulation of toxic byproducts and the effects of aspirin and caffeine.

Potential Signs of Overdose

Component Symptoms of Toxicity (Severe or Delayed)
Acetaminophen Signs of liver damage: upper abdominal pain, dark urine, clay-colored stools, jaundice (yellowing of skin or eyes).
Aspirin Ringing in the ears (tinnitus), hearing loss, confusion, rapid or deep breathing.
Caffeine Severe restlessness, tremors, rapid or irregular heartbeat, seizures.

When to Seek Emergency Help

Call for emergency medical help immediately if you or someone else has taken more than the prescribed or recommended dose, or if any of the following severe symptoms occur: yellowing of the skin or eyes, dark urine, blood in vomit (vomit that looks like coffee grounds) or stools (black or tarry stools), severe confusion, hallucinations, seizures, or loss of consciousness. Early treatment is crucial, especially for acetaminophen-related liver toxicity, even if initial symptoms are mild or absent.

Therapeutic Uses of P-A-C

What P-A-C Treats: Main Uses and Benefits

P-A-C is used as a therapeutic component in the management of specific types of discomfort and related symptoms. It is employed for the temporary relief of minor aches associated with headaches, muscle strains, toothaches, and discomfort from the common cold or minor fevers. The primary benefit offered by this medication is supporting the reduction of immediate physical distress, enabling individuals to maintain their routines.

Its use is indicated in clinical scenarios where patients require assistance with acute, episodic physical discomfort. It is also a supportive measure in the management of symptoms associated with certain inflammatory conditions.

Quick Fact: P-A-C is used as an approach to achieve temporary relief of common minor aches and related symptoms.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility profile for P-A-C (Acetylsalicylic Acid and Caffeine) is formally defined by regulatory agencies, primarily around the risks associated with the NSAID component, which determines who can use the medicine and who is absolutely restricted.

Contraindicated Populations

Category Official Regulatory Statement
Hypersensitivity Patients with known hypersensitivity to Aspirin, Caffeine, or any other Nonsteroidal Anti-inflammatory Drug (NSAID).
GI Disease Individuals with active gastric or intestinal ulceration or a history of recurrent peptic ulcer disease or active bleeding disorders.
Organ Failure Patients with severe hepatic failure (liver disease) or severe renal impairment (kidney disease).
Late Pregnancy Use is strictly contraindicated during the last trimester of pregnancy.

Age- and Condition-Based Restrictions

  • Pediatric Use: The medicine is not recommended for children and teenagers with flu symptoms or chickenpox due to the association with Reye's syndrome. Use in children younger than 12 years of age generally requires medical consultation.
  • Geriatric Use: Older adults (age 60 or older) should use P-A-C with caution due to a documented increased risk of gastrointestinal bleeding.
  • Conditional Use: Caution is advised for individuals with pre-existing conditions such as heart disease, uncontrolled high blood pressure, asthma, or gout. Use during the first and second trimesters of pregnancy or while breastfeeding should be avoided or is limited to the lowest effective dose for the shortest duration, as both ingredients are excreted into breast milk.

These statements define non-eligibility based on clinical risks, ensuring that use is limited to approved adult and adolescent populations under standard labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interaction patterns for P-A-C (Acetylsalicylic Acid and Caffeine) based on their potential to alter systemic exposure or increase adverse risks. The interaction profile establishes specific restrictions and monitoring requirements when combined with certain medicinal products and substances.

Formal Interaction Restrictions

Interacting Substance/Class Documented Outcome/Classification
Methotrexate (ge 15 mg/week) Contraindicated due to risk of increased toxicity via delayed excretion.
Other NSAIDs and COX-2 Inhibitors Co-administration avoided due to heightened risk of gastrointestinal adverse effects.
Alcohol Restricted due to significantly increased risk of gastrointestinal haemorrhage.
Excessive Caffeine Intake Restricted to prevent excessive systemic stimulation.

Interactions Affecting Exposure and Efficacy

Co-administration with Anticoagulants (e.g., Warfarin) and Antiplatelet Agents results in an increased risk of bleeding due to the additive effects of Acetylsalicylic Acid. The medicine may also decrease the efficacy of Diuretics and Antihypertensive Agents (such as ACE inhibitors). Furthermore, Acetylsalicylic Acid is documented to inhibit the metabolism of Valproate, potentially leading to increased systemic toxicity for that agent. The Caffeine component can also increase the elimination of Lithium. Regulatory notes recommend periodic blood pressure monitoring for elderly patients using this combination with antihypertensive medication.

Mechanism of Action

Peripheral Suppression of Signal Transmission

The action of Acetylsalicylic Acid (ASA) at its molecular target is defined by its function as an irreversible inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). This mechanism blocks the synthesis of Prostaglandins ( PGE2) in peripheral tissues. The resulting reduction in PGE2 prevents the chemical sensitization of nociceptors (pain receptors), thereby reducing the transmission of signals from the periphery and contributing to the resetting of the hypothalamic thermoregulatory set point.

Central Modulation via Adenosine Receptor Antagonism

Caffeine exerts its central activity as a competitive antagonist at inhibitory Adenosine Receptors (A1 and A2A) in the brain. By blocking the binding of endogenous Adenosine, this mechanism relieves inhibitory tone on neural activity, resulting in increased central neuronal excitability. This antagonism also induces cerebral vasoconstriction (narrowing of blood vessels in the brain), which complements the peripheral mechanism and acts as a pharmacodynamic adjuvant, combining peripheral and central actions to shape the resulting physiological profile.

Dosage and Administration Information

How to Use P-A-C: Administration

The administration of P-A-C follows specific parameters that define the dose, route, timing, and preparation steps. These elements establish a framework for the consistent use of the medicine.

Administration Scope

Element Instruction
Route of Administration Must be administered via [Route, e.g., Oral].
Dosing Schedule Initial Dose: [X] mg once daily. Maintenance Dose: [Y] mg, not to exceed [Z] mg per day.
Timing in Relation to Meals Take [e.g., With food / Without regard to meals].
Preparation Requirements [If applicable, e.g., Swallow tablet whole; do not crush or chew. / Reconstitute powder with V mL of sterile water].
Age-Group Rules Geriatric Use (ge 65 years): [e.g., Start at half the standard dose]. Pediatric Use: [e.g., Use weight-based dosing M mg/kg].
Missed-Dose Rules If a dose is missed, take it as soon as remembered, unless it is within [H] hours of the next scheduled dose; do not double the dose.

Resulting Procedural Structure

The usage protocol involves a specific sequence of actions:

  1. Confirm the specific dose and dosage form required for the patient's condition and characteristics.
  2. Execute any mandated preparation steps, such as reconstitution or shaking, exactly as documented.
  3. Administer the medicine via the specified route (e.g., oral or intravenous injection) at the required frequency (e.g., once daily) and specified time of day.
  4. Adhere to any special conditions, such as required infusion rates or application site instructions.
  5. Follow the rules for managing a missed dose to maintain the designated treatment schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for P-A-C

The research evidence for P-A-C, a fixed-dose combination of Acetylsalicylic Acid and Caffeine, is found in clinical evaluations and authoritative scientific literature. Research examined this combination structure in conditions characterized by fluctuating or episodic manifestations, such as various types of acute pain. This evidence base documents the patient-reported outcomes describing perceived discomfort that were measured during the study periods.


Evidence for Use in Episodic Tension-Type Headache

Research examined the combination structure for Episodic Tension-Type Headache using short-term, acute Randomized Controlled Trials (RCTs) and systematic reviews. Studies typically involved adults experiencing headache episodes and monitored outcomes related to physical discomfort, such as measurements of pain intensity and the monitoring of pain status. The body of evidence pertaining to this fixed-dose combination structure in this context is generally described as having a High level of consistency across scientific reviews.


Evidence for Use in Acute Migraine Attacks

Research also examined the P-A-C combination in Acute Migraine Attacks, focusing on episodes where symptoms become more noticeable. Studies monitored outcomes linked to the acute phases of heightened symptom activity, particularly focusing on the monitoring of pain status at two hours post-dose. Data show patterns related to short-term changes in these patient-reported outcomes describing perceived discomfort.


Key Limitations and Areas of Research Uncertainty

A significant limitation is that the highest-level meta-analyses often include studies of the triple combination (ASA, Acetaminophen, and Caffeine). This means that specific comparative evidence showing the distinct contribution of the dual ASA/Caffeine combination in all scenarios is sometimes lacking. Furthermore, evidence quality varies across studies when examining specific subgroups, and data for certain groups, such as older adults, remain insufficient. The research is focused on acute administration, meaning long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about P-A-C (FAQ)

Q: Is P-A-C the same type of drug as its generic version?

According to regulatory standards, the generic version of P-A-C must contain the identical active ingredients—Acetylsalicylic Acid and Caffeine—in the same strength as the brand-name medicine. The generic version is generally expected to be considered equivalent in terms of content and performance.


Q: Is P-A-C considered a long-term or a short-term treatment?

Regulatory sources describe P-A-C as being generally used for acute, short-term use for mild to moderate pain relief. Research examining the long-term effects of use over extended periods is often described as not fully established in authoritative summaries.


Q: How does the body process P-A-C after it is taken?

Official clinical pharmacology data describes the body's handling of P-A-C. The medicine is primarily processed in the liver, where Acetylsalicylic Acid is rapidly converted into its active metabolite, salicylate. The Caffeine component is also metabolized by specific liver enzymes.


Q: Does P-A-C treat the cause of the condition or just the symptoms?

P-A-C is classified as an analgesic combination, meaning its purpose is to relieve discomfort and manage pain signals, or symptoms. Its mechanism of action works by blocking the synthesis of pain-signaling chemicals like Prostaglandins, not by addressing the underlying cause of the condition.


Q: Can the effectiveness of P-A-C be reduced by light or heat?

Regulatory storage instructions require the medicine to be protected from excessive heat and moisture to ensure the stability of the ingredients. Specific warnings about protection from light are sometimes detailed on the product's official label.


Q: Is P-A-C a medication that needs to be taken at the exact same time every day?

Official labeling specifies the frequency for taking the medicine, such as once daily. Official documents emphasize the importance of following a consistent schedule for the designated treatment plan.


Q: How long does P-A-C stay in a person's system after the last dose?

Pharmacokinetic data from regulatory sources tracks the active components in the body. The half-life of salicylate, the active metabolite, ranges between 3.5 and 4.5 hours in the circulation, and the half-life of the caffeine component is approximately 4 to 5 hours.


Q: What are the signs that P-A-C is starting to work as expected?

P-A-C is intended to provide swift relief from mild to moderate pain. In clinical studies, effects were measured by monitoring patient-reported changes in pain intensity and overall pain status.


Q: Are there any known long-term side effects associated with using P-A-C?

Official safety profiles note that the risk of serious effects, such as gastrointestinal hemorrhage and ulceration, is documented to be associated with the Acetylsalicylic Acid component. This risk is particularly noted with long-term use or higher doses.


Q: Does P-A-C typically cause drowsiness or affect alertness?

Common adverse reactions related to the nervous system are listed in official documents as dizziness, insomnia, and nervousness. These effects can impact alertness, but drowsiness is not typically listed as a common effect.


Q: Does stopping P-A-C suddenly cause any specific effects?

Official labeling for this acute pain reliever does not typically contain specific information about effects upon sudden cessation. This is because the medicine is generally used for a short duration.


Q: Can P-A-C be taken with common pain relievers like ibuprofen or acetaminophen?

Official documentation lists co-use with other NSAIDs (like ibuprofen) as avoided due to heightened side effect risks. Regulatory sources detail specific restrictions for co-administration with any other drug containing acetaminophen to prevent accidental overdose.


Q: Is there a list of specific foods or beverages to avoid when on P-A-C?

Official warnings restrict co-use with alcohol due to the risk of gastrointestinal bleeding. Restrictions are also noted for intake of beverages or foods containing excessive caffeine to prevent overstimulation.


Q: Can herbal supplements like St. John's Wort affect how P-A-C works?

The combination has potential interactions with certain herbal supplements. For example, official sources indicate that St. John's Wort may affect how the body processes the medicine or increase the risk of specific adverse effects.


Q: Is P-A-C safe for use in older patients (the elderly)?

Official guidance states that older adults (ge 60) are in a population that requires caution when the medicine is used. This is due to a documented increased risk of gastrointestinal bleeding in this population.


Q: Is P-A-C approved for use in children or adolescents?

Official information states the medicine is generally approved for use in adults and adolescents 12 years of age and older. There are specific cautions or contraindications for children and teenagers with viral illnesses.


Q: Does P-A-C have any effects related to fertility?

Regulatory information for the Acetylsalicylic Acid component of P-A-C addresses reproductive health. Official data states there is no conclusive evidence from animal studies regarding impairment of fertility.


Q: What is the general success rate of P-A-C in clinical trials?

Clinical research documents a High level of consistency across studies concerning patient-reported outcomes for relief from acute pain. However, no single 'success rate' percentage is published in authoritative summaries for the combination.


Q: What is the difference between an FDA-approved drug and one used off-label?

A drug is considered approved by the FDA (or equivalent agency) when its benefits for a specific use are determined to outweigh the risks. Off-label use refers to using the drug for a condition or dosage not included in that official approved label.


Q: Why are there sometimes warnings about driving or operating machinery when taking P-A-C?

Warnings about driving are related to common nervous system side effects listed in the official safety profile. These include effects like dizziness and nervousness, which may impair a person's ability to safely operate heavy machinery or vehicles.

How should P-A-C be stored and disposed of?

How to Store and Dispose of P-A-C

P-A-C (Acetylsalicylic Acid and Caffeine) must be stored and handled according to regulatory standards to maintain the stability of the ingredients.


Storage Requirements

The medicine is required to be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is essential to protect the product from moisture and excessive heat; the product label explicitly states do not freeze.

Always keep P-A-C in its original container and ensure the cap or lid is tightly closed to prevent moisture exposure. For safety, the medicine must be kept out of the sight and reach of children and safety caps must be locked.


Disposal Instructions

Unused or expired P-A-C should be disposed of according to local regulatory requirements for pharmaceutical waste. If a drug take-back program is unavailable, official guidelines recommend removing the medication from its packaging, mixing it with an unappealing substance, and placing the mixture in a sealed bag for disposal in the household trash. Do not flush the medicine down the toilet unless the product labeling specifically instructs it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of P-A-C found in:

A-Z Index: